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SUMMARY
Pancreatic cancer is a deadly disease characterized by late diagnosis and resistance to therapy. Much
progress has been made in defining gene defects in pancreatic cancer, but a full accounting of its molecular
pathogenesis remains to be provided. Here, we show that expression of the ataxia-telangiectasia group D
complementing gene (ATDC), also called TRIM29, is elevated in most invasive pancreatic cancers and
pancreatic cancer precursor lesions. ATDC promoted cancer cell proliferation in vitro and enhanced tumor
growth and metastasis in vivo. ATDC expression correlated with elevated b-catenin levels in pancreatic
cancer, and b-catenin function was required for ATDC’s oncogenic effects. ATDC was found to stabilize
b-catenin via ATDC-induced effects on the Disheveled-2 protein, a negative regulator of glycogen synthase
kinase 3b in the Wnt/b-catenin signaling pathway.INTRODUCTION
Pancreatic cancer is a highly lethal disease that is often diag-
nosed in an advanced state. In fact, though it is the fourth
most common cause of cancer death in theUnited States, result-
ing in 37,000 deaths per year (Jemal et al., 2007), it has the worst
prognosis of any major malignancy (<5% 5-year survival rate).
Recent advances in surgical and medical therapy have had
only a modest impact on pancreatic cancer mortality. A major
hallmark of pancreatic cancer is extensive local tumor invasionand early systemic dissemination. Pancreatic cancer is also
notoriously resistant to chemotherapy and ionizing radiation.
To further understand the molecular pathogenesis of pancre-
atic cancer, genomic and proteomic profiling has been per-
formed to identify differentially expressed genes and proteins
that might represent novel therapeutic targets (Cao et al.,
2004; Chen et al., 2005; Logsdon et al., 2003; Lowe et al.,
2007). Using Affymetrix gene expression profiling, we previously
found that pancreatic cancer cells overexpress the ataxia-telan-
giectasia group D complementing gene (ATDC) at an averageSIGNIFICANCE
Pancreatic cancer is an aggressive malignancy, and an improved understanding of themolecular mechanisms governing its
highly aggressive behavior is needed formore effective treatment, early detection, and prevention. Defects inWnt/b-catenin
signaling are common in certain cancers, such as colorectal carcinoma, and recent evidence suggests that Wnt/b-catenin
signalingmay contribute to pancreatic cancer. In this report, we show that the ataxia-telangiectasia groupD complementing
gene (ATDC) is overexpressed in themajority of invasive pancreatic cancers and pancreatic cancer precursor lesions. ATDC
contributes to pancreatic cancer via its ability to interact with and stabilize expression of Disheveled-2, with resultant stabi-
lization of b-catenin. Besides highlighting ATDC as a potential therapeutic target in pancreatic cancer, our studies have
defined a mechanism for activating Wnt/b-catenin signaling in cancer.Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc. 207
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ATDC in Pancreatic Cancerlevel 20-fold higher than epithelial cells from normal pancreas or
chronic pancreatitis-derived tissues (Logsdon et al., 2003).
ATDCwas initially described in the hunt for the gene responsible
for the genetic disorder ataxia-telangiectasia (AT) (Kapp et al.,
1992). Both alleles of the ATDC gene in an AT patient-derived
cell line were found to contain early stop codon mutations
leading to a truncated and nonfunctional ATDC protein (Tauchi
et al., 2000). No germline ATDC mutations were found in AT
patients, and subsequently the gene responsible for AT was
identified as ataxia-telangiectasia mutated (ATM) (Savitsky
et al., 1995).
The ATDC gene, located at chromosome 11q23, encodes
a 588 amino acid protein with multiple zinc-finger motifs and an
adjacent leucine-zipper motif that may allow the ATDC protein
to form homo- or heterodimers (Kapp et al., 1992). Northern
blot analysis revealed that ATDC is normally expressed in
placenta, lung, thymus, prostate, testis, and colon, while no
expression is observed in heart, brain, skeletalmuscle, pancreas,
spleen, ovary, or small intestine (Hosoi and Kapp, 1994). In addi-
tion to our observation of high ATDC levels in primary pancreatic
cancers and pancreatic cancer cell lines, a search of the Onco-
mine database (http://www.oncomine.org/) revealed that ATDC
has been reported to be overexpressed in lung (Hawthorn et al.,
2006), bladder (Dyrskjot et al., 2004), colorectal (Glebov et al.,
2006; Ohmachi et al., 2006), ovarian (Santin et al., 2004), and
endometrial cancers (Mutter et al., 2001) and inmultiplemyeloma
(Zhan et al., 2002), with apparent reduced expression in mela-
noma (Smith et al., 2005) and in breast (Nacht et al., 1999),
head and neck (Zhang et al., 2006), and prostate cancers (LaTu-
lippe et al., 2002; Luo et al., 2001; Yu et al., 2004). A recent report
identified a correlation between ATDC expression in gastric
cancer and poor histological grade, large tumor size, extent of
tumor invasion, and lymph nodemetastasis (Kosaka et al., 2007).
The ATDC protein, also known as TRIM29, is a member of the
tripartite motif (TRIM) family. TRIM proteins have a series of
conserved domains, which include a RING (R), a B box type 1
(B1) and B box type 2 (B2), and a coiled-coil (CC) region. While
some of the domains may be absent or present in the different
TRIM proteins (ATDC contains the B1-B2-CC domains but lacks
the R domain), their order is always maintained (R-B1-B2-CC)
(Reymond et al., 2001). Proteins belonging to the TRIM family
have been implicated in a variety of cellular processes, such as
development and growth, and in several human diseases,
including HIV infection (Stremlau et al., 2004) and leukemia (God-
dardetal., 1991).The functionofATDChasnotbeenstudiedprevi-
ously in any physiologic or pathologic process, though the ATDC
protein appears to be localized primarily to the cytoplasm (Rey-
mond et al., 2001). In this report, we describe our data examining
the expression and functional role of ATDC in pancreatic cancer.
RESULTS
ATDC Is Overexpressed in Human Pancreatic
Adenocarcinoma
To identify genes with potential roles in the development and
progression of pancreatic adenocarcinoma, we assessed gene
expression in microdissected samples of human pancreatic
carcinoma using Affymetrix arrays.We compared the expression
patterns in cancer tissues to those seen in normal pancreas and208 Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc.chronic pancreatitis, the latter of which served as an important
control for the extensive fibrosis typically observed with pancre-
atic cancer (Logsdon et al., 2003). One of the most highly upre-
gulated genes was the ATDC gene, which showed elevated
expression in 10 out of 10 samples of pancreatic cancers relative
to normal pancreas or chronic pancreatitis samples (Figure 1A).
On average, ATDC expression was roughly 20-fold higher in
pancreatic adenocarcinomas. The gene expression data were
further confirmed in an analysis of ATDCmRNA levels of pancre-
atic cancer using quantitative real-time RT-PCR (qRT-PCR)
(Figure 1B). Immunohistochemical staining confirmed that
ATDC protein expression was present in the neoplastic epithe-
lium of pancreatic cancer (Figure 1C).
A pancreatic cancer progression model is now widely
accepted in which normal pancreatic ductal epithelium prog-
resses to infiltrating cancer through a series of morphologically
defined pancreatic precursors called pancreatic intraepithelial
neoplasias (PanINs) (Hruban et al., 2000). This progression is
associated with accumulation of specific genetic changes,
such as K-ras mutations and inactivation of p16, that are
observed in invasive pancreatic cancer. We found that ATDC
was not expressed in PanIN 1 lesions (0 of 4) but was occasion-
ally expressed in PanIN 2 lesions (1 of 7) and was more often
expressed in PanIN 3 lesions (3 of 6) (Figure 1D). These data
suggest that upregulation of ATDC occurs prior to the develop-
ment of invasive pancreatic cancer.
ATDC Promotes Cellular Proliferation In Vitro
and Pancreatic Tumorigenesis In Vivo
To understand the function of ATDC in pancreatic cancer, we
first explored the effect of ectopic ATDC expression on cellular
growth in vitro in multiple cell lines with differing levels of endog-
enous ATDC expression. Following transfection with an ATDC
cDNA expression construct, HEK293 cells, which normally do
not express ATDC, and MiaPaCa2 pancreatic cancer cells,
which express low endogenous levels of ATDC, demonstrated
a significant increase in cellular proliferation (Figures 2A and
2B). Similar changes were observed in monoclonal and poly-
clonal HEK293 cells lines stably overexpressing ATDC (see
Figure S1 available online). Conversely, cellular proliferation
was attenuated when endogenous ATDC expression was
silenced by stable transfection with two different shRNA vectors
targeting distinct regions of ATDC in Panc1 and BxPC3 pancre-
atic cancer cell lines, both of which have high endogenous levels
of ATDC (Figures 2C and 2D). Expression of ATDC shRNAs 1 and
2 did not alter basal cell proliferation rates in HEK293 cells
(Figure S2), verifying the specificity of the inhibitory function of
the ATDC shRNAs on ATDC’s function.
To examine the effects of ATDC silencing on pancreatic tumor
growth in vivo, we infected Panc1 cells expressing a control
shRNA or ATDC shRNA1 with a luciferase-expressing lentivirus.
Following injection of 5 3 105 cells into the tail of the pancreas,
tumor growth was assessed using bioluminescent imaging (n =
8 animals per group). All of the animals injected with Panc1 cells
expressing control shRNA demonstrated tumor formation 14
days postinjection, while tumors were not detected in the
animals injected with Panc1 ATDC shRNA cells (Figure 2E, left
panels). At 60 days postinjection, the control shRNA animals’
tumors grew significantly larger, with evidence of metastatic
Cancer Cell
ATDC in Pancreatic CancerFigure 1. ATDC Is Highly Expressed in Human Pancreatic Cancer
(A) cDNA microarray analysis (Logsdon et al., 2003) was performed using Affymetrix HuGeneFL arrays containing 7129 probe sets. Microdissected samples of
human pancreatic cancer (n = 10, white bars), normal pancreas (n = 5, black bars), and chronic pancreatitis (n = 5, gray bars) were analyzed. mRNA expression
levels of ATDC were expressed as Affymetrix units.
(B) Validation of microarray results of ATDC mRNA levels using quantitative real-time RT-PCR analysis.
(C) ATDC immunostaining of representative samples of normal pancreas, pancreatic cancer, and chronic pancreatitis. Scale bars = 100 mm.
(D) Immunohistochemical examination of ATDC expression in normal pancreas or pancreatic intraepithelial neoplasia (PanIN) lesions. Scale bars = 100 mm.spread, while only 25% (2 of 8) of the ATDC shRNA animals
demonstrated evidence of macroscopic tumors (Figure 2E, right
panels; Figure 2F). The mean tumor volume was significantly
larger in the tumors grown in mice injected with Panc1 cells
expressing control shRNA compared to mice injected with
Panc1 cells expressing ATDC shRNA (203.2 ± 68.8 versus 2.01
± 1.0 mm3; p < 0.05) (Figure 2G). These data support the role
of ATDC in promoting growth of pancreatic cancer cells.
ATDC Activates the Wnt/b-Catenin/TCF
Signaling Cascade
In exploring possible downstream mediators of ATDC’s growth-
promoting effects, we noted that overexpression of ATDC
resulted in a significant increase in b-catenin levels in HEK293
cells (Figure 3A). In addition, the overexpression of ATDC
increased expression of the under- or nonphosphorylated forms
of b-catenin (‘‘active’’ b-catenin) presumed to be the forms of
b-catenin responsible for mediating Wnt signaling in cells (van
Noort et al., 2002) (Figure 3A). Similar results were obtained in
MiaPaCa2 pancreatic cancer cells ectopically expressing
ATDC (Figure 3B). Conversely, ATDC shRNA1- or 2-mediated
silencing of endogenous ATDC expression significantly
decreased total b-catenin and active b-catenin levels in Panc1
cells (Figures 3C and 3E) and BxPC3 cells (Figures 3D and 3F).
The active form of b-catenin exerts its growth-promoting
effects by translocating from the cytoplasm to the nucleus,
where it binds to transcription factors such as the T cell factor
(TCF)/lymphoid enhancer-binding factor and thereby stimulatesthe transcription of Wnt target genes (Clevers, 2006). Overex-
pression of ATDC in HEK293 and MiaPaCa2 cells increased
expression of the Wnt/b-catenin target genes c-Myc and Dick-
kopf homolog 1 (DKK1) (Figures 3A and 3B), while c-Myc and
DKK1 levels were significantly reduced in Panc1 and BxPC3
cells expressing ATDC-targeting shRNA1 or 2 (Figures 3C and
3D). Consistent with the ability of ATDC to increase b-catenin
levels in HEK293 cells, we found that ATDC strongly activated
the TCF-dependent TOPflash reporter construct in HEK293 cells
(Figure 3G). Together, these results strongly suggest that ATDC
enhances b-catenin levels and activates b-catenin/TCF target
gene expression in pancreatic cancer cells.
ATDC Increases the Free Intracellular Pool of b-Catenin
through Activation of the Canonical Wnt Signaling
Pathway
To address in more detail the means by which ATDC increases
b-catenin/TCF-regulatedgeneexpression,weassessed theabun-
dance of the free pool of b-catenin in ATDC-expressing cells
compared to control cells. To measure the free pool of b-catenin,
we utilized a recombinant glutathione S-transferase (GST) fusion
protein containing the cytoplasmic tail of E-cadherin (GST-Ecad).
It has been previously shown that GST-Ecad can readily be used
tomonitor the abundanceof the freepool ofb-catenin that is stabi-
lized in response to activation of theWnt signaling pathway (Winer
etal., 2006).Asshown inFigure3H, followingectopicexpressionof
ATDCor theS33Ymutant formofb-catenin inHEK293cells, signif-
icant increases in the levels of the freeb-catenin poolwere seen asCancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc. 209
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ATDC in Pancreatic CancerFigure 2. ATDC Promotes Cell Proliferation and Pancreatic Tumorigenesis
(A) Top: medium or high expression of ATDC in stably transfected HEK293 cells. Bottom: MTS proliferation assay in ATDC-transfected HEK293 cells (mean ±
SEM; n = 4, *p < 0.05 versus empty vector-transfected cells).
(B) Top: ATDC expression in wild-type (WT), empty vector-transfected, or ATDC-transfected MiaPaCa2 cells. Bottom: MTS proliferation assay in ATDC-
transfected MiaPaCa2 cells (mean ± SEM; n = 3, *p < 0.05 versus empty vector-transfected cells).
(C and D) Top: ATDC expression in wild-type, control shRNA-transfected, and ATDC shRNA1- or 2-transfected Panc1 cells (C) or BxPC3 cells (D). Bottom: MTS
proliferation assays in ATDC shRNA-transfected Panc1 and BxPC3 cells (mean ± SEM; n = 4, *p < 0.05 versus wild-type cells).
(E) Representative bioluminescent images of half of the animals in the control or ATDC shRNA groups are shown at 14 (left panels) and 60 (right panels) days after
injection, depicting the extent of tumor burden.
(F) Representative pictures 60 days after injection of mouse pancreatawith control shRNA- or ATDC shRNA-transfected Panc1 cells. Only 25%of themice (2 of 8)
injected with Panc1 cells expressing ATDC shRNA displayed evidence of tumor formation.
(G) Average tumor volume 60 days after injection in animals injected with control shRNA- or ATDC shRNA-transfected Panc1 cells (mean ± SEM; n = 3, *p < 0.05).demonstrated by the recovery of b-catenin with GST-Ecad. In
contrast, no significant b-catenin was recovered from control cell
lysates following incubation with GST-Ecad.
To confirm that the increase in the free pool of b-catenin seen
with ATDC overexpression was associated with increased cyto-
plasmic and nuclear levels of b-catenin, extracts from control
and ATDC-overexpressing HEK293 cells were separated into
membrane, cytoplasmic, and nuclear fractions, and the relative
abundance of b-catenin in these fractions was analyzed. ATDC
overexpression increased both the nuclear and cytoplasmic
fractions of b-catenin while having no effect on the membrane-
bound fraction of ATDC (Figure 3I). Previous reports have
demonstrated an important role for b-catenin in cell adhesion
as a part of a protein complex that includes E-cadherin. The E-
cadherin expression pattern in pancreatic cancer cells was unal-
tered by ATDC shRNA (Figure S3), suggesting that increased
levels of ATDC affect b-catenin levels and b-catenin/TCF-depen-
dent transcription in a fashion similar to that seen following acti-
vation of the canonical Wnt signaling pathway.210 Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc.ATDC Stimulates Cell Proliferation and Tumor Growth
via b-Catenin/TCF Activation
We next sought to determine whether the growth-promoting
effects of ATDC are mediated by activation of the b-catenin
signaling pathway. Constitutive activation of Wnt/b-catenin
signaling by mutations in known Wnt pathway components,
such as inactivatingmutations in theAPC (adenomatous polypo-
sis coli) or Axin1 tumor suppressor genes, or activating muta-
tions in b-catenin are commonly seen in certain cancers, such
as colorectal or hepatocellular carcinomas, but are rarely seen
in pancreatic adenocarcinoma (Gregorieff and Clevers, 2005;
Lustig and Behrens, 2003). However, constitutive activation of
b-catenin/TCF-dependent transcription, independent of muta-
tions, has been suggested to play an important role in the devel-
opment of certain human breast and ovarian cancers (Bafico
et al., 2004) and in mouse models of basal cell carcinoma
(Hoseong Yang et al., 2008) and pancreatic cancer (Pasca di
Magliano et al., 2007). To address the contribution of b-cate-
nin/TCF transcription in the growth-promoting effects of ATDC,
Cancer Cell
ATDC in Pancreatic CancerFigure 3. ATDC Upregulates b-Catenin Levels and TCF Transcriptional Activity
(A and B) Representative western blots of wild-type, empty vector-transfected, and ATDC-transfected HEK293 (A) and MiaPaCa2 cells (B). Overexpression of
ATDC results in upregulation of b-catenin, active b-catenin, and the T cell factor (TCF) target genes DKK1 and c-Myc. b-actin was used as a loading control.
(C and D) Representative western blots of Panc1 (C) and BxPC3 (D) cells expressing control shRNA, ATDC shRNA1 or 2. Silencing of ATDC in Panc1 and BxPC3
cells decreases levels of active b-catenin, DKK1 and c-Myc. b-actin was used as a loading control.
(E and F) Photomicrographs of control shRNA- and ATDC shRNA1-expressing Panc1 cells (E) and BxPC3 cells (F) immunostainedwith an anti-b-catenin antibody
(green). Cell nuclei were counterstained with DAPI (blue).
(G) TCF reporter activity was assessed using the b-catenin-responsive TOPflash reporter and the mutant control FOPflash reporter in HEK293 cells stably trans-
fected with empty vector or an ATDC expression vector (mean ± SEM; *p < 0.05 versus empty vector-transfected cells).
(H) The GST-E-cadherin (GST-Ecad) fusion protein detects increases in the free b-catenin pool. HEK293 cells expressing ATDC or S33Y b-catenin were har-
vested. Free b-catenin levels were assessed by western blotting of GST-Ecad-bound fractions of cell lysate using a specific anti-b-catenin antibody. b-actin
(input) was used as a loading control.
(I) Representative blots of b-catenin levels in membrane (Mem), nuclear (Nuc), and cytoplasmic (Cyto) fractions and total lysates (Lys). Fibrillarin (nuclear expres-
sion) and b-actin (cytoplasmic expression) were used as loading controls.we ectopically expressed a b-catenin shRNA or a dominant-
negative TCF (dnTCF) protein in either control vector-transfected
or ATDC-expressing HEK293 and MiaPaCa2 cells. Transfection
of either the b-catenin shRNA or dnTCF constructs significantly
inhibited ATDC-induced TOPflash reporter activity (Figures 4A
and 4B, upper panels) and cell proliferation (Figures 4A and
4B, lower panels) in HEK293 and MiaPaCa2 cells. Similarly,
transfection of b-catenin-targeting shRNA or dnTCF in Panc1
cells inhibited TOPflash reporter activity (Figure 4C, upper panel)
and inhibited the enhanced cellular proliferation seen in Panc1
cells in the setting of elevated endogenous ATDC levels
(Figure 4C, lower panel).
To examine the effects of b-catenin silencing on pancreatic
tumor growth in vivo, we infected control or b-catenin shRNA-
transduced Panc1 cells with a luciferase-expressing lentivirus.Following injection of 5 3 105 cells into the tail of the pancreas,
tumor growth was assessed using bioluminescent imaging
(n = 8 animals per group). All of the animals injected with
Panc1 cells expressing control shRNA demonstrated tumor
formation 14 days postinjection, while tumors were not detected
in the animals injected with Panc1 cells expressing the b-catenin
shRNA (Figure 4D, left panels; three representative animals are
shown). At 60 days postinjection, the control tumors grew signif-
icantly larger, with evidence of metastatic spread, while the
extent of primary tumor size and metastasis was markedly
diminished in animals injected with Panc1 cells expressing the
b-catenin shRNA (Figure 4D, right panels), similar to the effects
observed with silencing ATDC in Panc1 cells (Figure 2E).
Western blot analysis of tumors derived from b-catenin
shRNA-transfected Panc1 cells harvested at 60 days afterCancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc. 211
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ATDC in Pancreatic CancerFigure 4. ATDC Stimulates Cell Proliferation and Tumor Growth via b-Catenin/TCF Activation
(A–C) In the upper panels, TCF reporter activity was measured using the b-catenin-responsive TOPflash reporter and the mutant control FOPflash reporter. The
effects of stable transfection of cells with dominant-negative TCF (dnTCF, black bars) and b-catenin shRNA (gray bars) on relative TCF activity are shown in
HEK293 (A) and MiaPaCa2 (B) cells (with empty or ATDC expression vector) or Panc1 cells (C) (with ATDC shRNA1 or 2 expression) (mean ± SEM; n = 3,
*p < 0.05 versus control, nontreated cells [white bars]). In the lower panels, the effects of stable transfection of dnTCF (black bars) and b-catenin shRNA
(gray bars) on cell proliferation are shown in HEK293 (A) and MiaPaCa2 (B) cells (with empty or ATDC expression vector) or Panc1 cells (C) (with ATDC shRNA1
or 2 expression) (mean ± SEM; n = 3, *p < 0.05 versus control, nontreated cells [white bars]).
(D) Representative bioluminescent images of animals in the control and ATDC shRNAgroups are shown at 14 (left panels) and 60 (right panels) days after injection,
depicting the extent of tumor burden.
(E) Western blotting verifies downregulation of b-catenin in tumors derived from b-catenin shRNA-transfected Panc1 cells harvested at 60 days.
(F) Average tumor volume 60 days after injection in animals injected with control shRNA- or b-catenin shRNA-transfected Panc1 cells (mean ± SEM; n = 3,
*p < 0.05).injection (Figure 4E) demonstrated effective silencing of b-cate-
nin (Figure 4E). The mean tumor volume was significantly greater
in the mice injected with Panc1-Luc cells expressing control
shRNA compared to mice injected with Panc1-Luc cells ex-
pressing b-catenin shRNA (251.5 ± 79.2 versus 35.2 ±
7.8 mm3, respectively; p < 0.05) (Figure 4F). Overall, these data
indicate that ATDC plays a key role in cell proliferation and tumor
growth and that ATDC’s growth-promoting effects are depen-
dent at least in part on the b-catenin/TCF signaling pathway.
Correlation between ATDC and b-Catenin Expression
in Pancreatic Adenocarcinoma
Based on our findings that ATDC is highly expressed in human
pancreatic cancers and that ATDC-mediated cancer cell growth
in pancreatic cancer cells is dependent on b-catenin signaling,
we predicted that ATDC and b-catenin expression levels would
be well correlated in pancreatic cancer cell lines and primary
pancreatic cancers. As shown in Figure 5A, the levels of ATDC
and b-catenin in pancreatic cancer cell lines correlated well,
with the highest levels of b-catenin being observed in BxPC3
cells, which have high levels of endogenous ATDC. Intermediate212 Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc.levels of b-catenin and ATDC proteins were found in Panc1 cells,
and both b-catenin and ATDC were minimally expressed in Mia-
PaCa2 cells. To further study the relationship of ATDC and b-cat-
enin expression in pancreatic cancer, immunohistochemical
analysis of ATDC and b-catenin in human pancreatic normal
and adenocarcinoma tissues was performed. We did not
observe ATDC staining in normal pancreas but did observe
expression of b-catenin localized to the cell membrane
(Figure 5B, left panels), as has been described previously (Pasca
di Magliano et al., 2007). It is commonly thought that both cyto-
plasmic and nuclear localization of b-catenin is an indicator of
active b-catenin signaling in the Wnt pathway (Fodde and Bra-
bletz, 2007). To assess the correlation between ATDC expres-
sion and b-catenin, we analyzed a pancreatic cancer tissue
microarray containing 47 pancreatic carcinoma samples. We
observed focal nuclear staining for b-catenin in 5 tumors (11%)
and elevated cytoplasmic levels of b-catenin in 24 tumors
(51%). These results correlate well with those previously pub-
lished on b-catenin expression in pancreatic cancer (Pasca di
Magliano et al., 2007). We observed a strong correlation
between ATDC and b-catenin expression in the 47 pancreatic
Cancer Cell
ATDC in Pancreatic Cancercarcinoma cases, with moderate to high expression of ATDC in
the cancer samples that showed elevated cytoplasmic and/or
nuclear b-catenin expression (Table S1). Representative
samples of pancreatic cancers shown in Figure 5B (middle and
right panels) demonstrate the correlation in ATDC and b-catenin
expression in cancer samples with moderate or high levels of
ATDC. Importantly, we did not find any evidence of pancreatic
cancers expressing elevated levels of b-catenin without
expressing high levels of ATDC, suggesting that elevated cyto-
plasmic and nuclear levels of b-catenin expression may in fact
be dependent on elevated expression of ATDC.
ATDC Interacts with Disheveled-2 and Components
of the b-Catenin Destruction Complex to Stabilize
b-Catenin
Wewere interested in defining themechanism by which elevated
levels of ATDC result in increased b-catenin expression. In the
absence of Wnt ligands, cytoplasmic levels of b-catenin are
regulated by a multiprotein complex termed the destruction
complex that contains axin, APC, and glycogen synthase
kinase-3b (GSK-3b). Axin and APC are believed to facilitate effi-
cient phosphorylation of b-catenin by GSK-3b at multiple serine
and threonine residues in its N terminus. Phosphorylated b-cat-
enin is then ubiquitinated, leading to its rapid proteasomal
degradation (Gordon and Nusse, 2006). To determine whether
ATDC increases b-catenin levels by stabilizing b-catenin,
Figure 5. Correlation between ATDC and b-Catenin Expression in
Pancreatic Cancer
(A) Western blot analysis of ATDC and b-catenin expression in BxPC3, Panc1,
and MiaPaCa2 cells. b-actin was used as a loading control.
(B) Immunohistochemical (IHC) staining of samples of normal human pancreas
(left panels) and human pancreatic adenocarcinomas (middle and right
panels). A correlation between ATDC and b-catenin expression in pancreatic
adenocarcinoma samples is evident. Scale bars = 50 mm. IHC scores are
graded as moderate (++, intermediate staining) or strong (+++, intense stain-
ing).Panc1 cells (with or without ATDC silencing) were incubated
with 10 mg/ml cycloheximide (CHX) to prevent new b-catenin
synthesis, and b-catenin levels were then measured, with levels
reflective of the rate of b-catenin protein degradation. Silencing
of ATDC expression significantly increased the b-catenin degra-
dation rate, resulting in a marked reduction in the levels of
remaining b-catenin (Figures S4A and S4B). This effect of
ATDC on b-catenin stability was validated by performing
a [35S]methionine pulse-chase assay. We found that b-catenin
was rapidly degraded in Panc1 cells in which ATDC expression
had been silenced compared to control Panc1 cells (Figures
6A and 6B).
To ascertain the mechanism by which ATDC stabilizes b-cat-
enin, we first examined whether ATDC interacts with the compo-
nents of the multiprotein complex that regulates b-catenin
stability. In coimmunoprecipitation experiments using anti-
bodies directed against axin, GSK-3b, and b-catenin, evidence
of complexes containing ATDC and axin and complexes con-
taining ATDC and GSK-3b was observed in HEK293 cells trans-
fectedwith a FLAG-taggedATDC construct (Figure 6C). To verify
that this interaction was physiologically relevant, we tested the
ability of endogenous ATDC in BxPC3 cells to interact with
axin and GSK-3b, and similar results were obtained
(Figure 6D). ATDC did not interact with b-catenin in either
HEK293 cells overexpressing ATDC or in BxPC3 cells (Figures
6C and 6D). These results are consistent with the possibility
that ATDC may interfere with GSK-3b-dependent phosphoryla-
tion of b-catenin by the destruction complex.
Based on the findings, we examinedwhether ATDCmight acti-
vate Disheveled (Dvl), a cytoplasmic protein that is activated by
binding of Wnt ligands to the Frizzled/low-density lipoprotein
receptor-related protein (LRP) coreceptor at the cell surface.
Activated Dvl binds to the axin/GSK-3b complex and antago-
nizes GSK-3b-dependent phosphorylation of b-catenin in
amanner not dissimilar to what we observed with ATDC. Indeed,
we found increased Dvl-2 levels (total and phosphorylated
forms) in HEK293 cells overexpressing ATDC as well as in
Panc1 and BXPC3 cells (Figures 6E–6G). Furthermore, silencing
of endogenous ATDC expression in Panc1 and BxPC3 cells
reduced the expression of Dvl-2 (Figures 6F and 6G). Increased
levels of Dvl-2 were present in primary pancreatic cancer
samples that had elevated expression of ATDC (Figure 6H).
Finally, immunohistochemical analysis revealed colocalization
of ATDC and Dvl-2 in ATDC-transfected HEK293 cells and
Panc1 cells (Figure S5). Coimmunoprecipitation experiments in
HEK293 cells and BxPC3 cells demonstrated that ATDC formed
a complex with Dvl-2 (Figures 6I and 6J). Complex formation
between ATDC and Dvl-1 or Dvl-3 in either ATDC-transfected
HEK293 or BxPC3 cells was not observed (data not shown).
To determine which region of the ATDC molecule interacts with
Dvl-2, we created a series of FLAG-tagged ATDC truncation
mutants and performed coimmunoprecipitation experiments.
We found that the ATDCD220 and ATDCD260 deletion mutants
were able to interact with Dvl-2 while the ATDCD348 mutant was
not, suggesting that amino acids 260–348 of ATDC, in a region
that contains a coiled-coil domain, interact with Dvl-2
(Figure S6).
We then tested whether modulating the levels of ATDC in cells
affects the abundance of Dvl-2 transcripts. Dvl-2 geneCancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc. 213
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ATDC in Pancreatic CancerFigure 6. ATDC Stabilizes b-Catenin by Interacting with Disheveled-2 and the b-Catenin Destruction Complex
(A) Pulse-chase assays in Panc1 cells (with or without ATDC silencing) were performed to determine b-catenin stability.
(B) b-catenin remaining in (A) was quantitated by densitometry at 0, 3, and 6 hr and normalized relative to the 0 hr time point. Results are the mean ± SEM of three
independent experiments (*p < 0.05 versus control shRNA cells at 6 hr).
(C and D) Cell lysates from HEK293 cells transfected with empty vector or FLAG-ATDC (C) and BxPC3 cells (D) were subjected to immunoprecipitation (IP) with
axin, GSK-3b, or b-catenin antibodies. Immunocomplexes were resolved by SDS-PAGE and subjected to western analysis with anti-FLAG antibody for HEK293
cells (C) and ATDC antibody for BxPC3 cells (D). Blotting with an anti-b-actin antibody showed equal loading.
(E–G) Lysates of HEK293 cells transfectedwith empty vector or ATDC expression vector (E) and control shRNA- or ATDC shRNA1- or 2- expressing Panc1 (F) and
BxPC3 cells (G) were subjected to western blotting with an anti-Dvl-2 antibody. The upper arrow indicates the phosphorylated form of Dvl-2, and the lower arrow
indicates the nonphosphorylated form. Experiments were performed twice with similar results.
(H) Western blotting of five samples each of pancreatic adenocarcinoma and normal pancreas. Dvl-1, Dvl-2, Dvl-3, and ATDC expression in pancreatic tissue
samples was measured. The experiments were repeated twice with similar results.
(I and J) Cell lysates from HEK293 cells transfected with empty vector (I) or FLAG-ATDC and BxPC3 cells (J) were subjected to IP with Dvl-2 or b-catenin anti-
bodies. Immunocomplexes were resolved by SDS-PAGE and subjected to western analysis with an anti-FLAG antibody for HEK293 cells (I) and ATDC antibody
for BxPC3 cells (J). Blotting with an anti-b-actin antibody showed equal loading.
(K) Pulse-chase assays were performed in Panc1 cells (with or without ATDC silencing) to determine Dvl-2 stability.
(L) Dvl-2 remaining in (K) was quantitated by densitometry at 0 and 6 hr and normalized relative to the 0 hr time point. Results are the mean ± SEM of three inde-
pendent experiments (*p < 0.05 versus control shRNA cells at 6 hr).expression, as measured by quantitative real-time RT-PCR, was
not altered in either HEK293 cells overexpressing ATDC or in
Panc1 cells with ATDC knockdown compared to control cells
(Figure S7). To examine whether ATDC might alter Dvl-2 levels
by affecting protein stability, [35S]methionine pulse-chase assays
were performed. Dvl-2 was rapidly degraded in Panc1 cells with
ATDC knockdown compared to control Panc1 cells (Figures 6K
and 6L), suggesting that ATDC forms a complex with Dvl-2 and
increases Dvl-2 levels by regulating Dvl-2 posttranscriptionally,
perhaps via direct effects on Dvl-2 protein stability.214 Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc.The Oncogenic Effects of ATDC Are Mediated by Dvl-2
To verify that the ability of ATDC to increase TCF activity and
cellular proliferation is mediated through Dvl-2, we transfected
two Dvl-2 shRNA constructs targeting different regions of Dvl-2
into HEK293 and MiaPaCa2 cells and examined the effects of
Dvl-2 knockdown on ATDC function. Both Dvl-2 shRNAs 1 and
2 were effective in knocking down levels of Dvl-2 in HEK293
and MiaPaCa2 cells (Figure S8). Knockdown of Dvl-2 in both
HEK293 and MiaPaCa2 cells overexpressing ATDC inhibited
increases in b-catenin levels (Figures 7A and 7B), TCF activity
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ATDC in Pancreatic CancerFigure 7. The Oncogenic Effects of ATDC Are Mediated by Dvl-2
(A and B) The effects of Dvl-2 shRNAs 1 and 2 on b-catenin expression is shown in representative western blots of HEK293 (A) and MiaPaCa2 cells (B) with or
without ATDC overexpression.
(C and D) TCF reporter activity was assessed in Dvl-2 shRNA1- or 2-transfected HEK293 (C) or MiaPaCa2 cells (D) with (+) or without () ATDC overexpression
(mean ± SEM; n = 3, *p < 0.05 versus empty vector-transfected cells).
(E and F) MTS proliferation assays in Dvl-2 shRNA1- or 2-transfected HEK293 (E) and MiaPaCa2 cells (F) with or without ATDC overexpression (mean ± SEM;
n = 3, *p < 0.05 versus wild-type cells).
(G) TCF reporter activity was measured in HEK293, SW480, DLD-1, and HCT116 cells with vector (white bars) or ATDC (black bars) transfection using the b-cat-
enin-responsive TOPflash reporter and the mutant control FOPflash reporter (mean ± SEM; n = 3, *p < 0.05).
(H) Cell proliferation of empty vector- and ATDC expression vector-transfected HEK293, SW480, DLD-1, and HCT116 cells is shown (mean ± SEM; n = 3,
*p < 0.05 versus control, nontreated cells).
(I) Varying amounts of wild-type b-catenin (b-cat) or constitutively active mutant b-catenin (S33Y) constructs with TOPflash or FOPflash reporter constructs were
cotransfected into Panc1 cells with control shRNA or ATDC shRNA expression. Forty-eight hours after transfection, TOPflash reporter assays were performed.
Data are presented as mean ± SEM; n = 3. *p < 0.05, control shRNA versus ATDC shRNA; **p < 0.01, Panc1 cells (ATDC shRNA) with b-catenin versus without
b-catenin or Panc1 cells (ATDC shRNA) with S33Y versus without S33Y.
(J) Varying amounts of wild-type b-catenin (b-cat) or constitutively active mutant b-catenin (S33Y) constructs were cotransfected into Panc1 cells with control
shRNA or ATDC shRNA expression. Forty-eight hours after transfection, cell growth rates were assessed. The experiments were repeated three times, and
data are expressed asmean ± SEM. *p < 0.05, control shRNA versus ATDC shRNA; **p < 0.01, Panc1 cells (ATDC shRNA) with b-catenin versus without b-catenin
or Panc1 cells (ATDC shRNA) with S33Y versus without S33Y.(Figures 7C and 7D), and cell proliferation (Figures 7E and 7F)
induced by ATDC.
If ATDC stabilizes b-catenin levels by acting on upstream
signaling events mediated by Dvl-2, then modulating ATDC
levels should not influence b-catenin levels in cell lines with
either APC or b-catenin mutations. Indeed, overexpression of
ATDC in the APC mutant SW480 and DLD-1 cell lines or the b-
catenin mutant HCT116 cell line did not alter TCF activity orcell proliferation as compared to control cells (Figures 7G and
7H). Furthermore, silencing of ATDC in Panc1 cells significantly
inhibited the increase in TOPflash reporter activity seen in
control Panc1 cells, and transfection with wild-type or a mutant
oncogenic form of b-catenin (S33Y) was able to reverse the
inhibitory effect of silencing of ATDC on TOPflash reporter
activity (Figure 7I) and cell proliferation (Figure 7J) in a dose-
dependent fashion.Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc. 215
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Our studies have identifiedATDCas a protein highly expressed in
the majority of human pancreatic adenocarcinomas and pancre-
atic cancer precursor lesions. We also have demonstrated that
expression of ATDC in pancreatic cancer cells promotes cellular
proliferation and enhanced tumor growth and metastasis. Addi-
tionally, we have provided evidence that elevated levels of
ATDC expression correlate with elevated b-catenin levels in
pancreatic cancer cell lines and primary pancreatic cancers,
and that silencing of ATDC via shRNA approaches antagonizes
b-catenin/TCF-mediated reporter activation and activation of
TCF target genes. b-catenin was implicated in the oncogenic
effects of ATDC in vitro and in vivo, and the ability of ATDC to
increase b-catenin levels appears to be attributable to ATDC’s
effects onDisheveled-2protein expression. In summary, our find-
ings implicate ATDC as an important positive regulator of b-cat-
enin-dependent signaling in pancreatic cancer.
ATDC has been reported to be upregulated in a number of
different cancer types, including lung, bladder, colorectal,
ovarian, and endometrial cancers and multiple myeloma (Dyrsk-
jot et al., 2004; Glebov et al., 2006; Hawthorn et al., 2006; Mutter
et al., 2001; Ohmachi et al., 2006; Santin et al., 2004; Zhan et al.,
2002). A recent report correlated ATDC expression in gastric
cancer with poor histological grade, large tumor size, extent of
tumor invasion, and lymph node metastasis (Kosaka et al.,
2007). ATDC has also been reported to be downregulated in
some cancer types (Ernst et al., 2002; Nacht et al., 1999; Smith
et al., 2005; Zhang et al., 2006), suggesting that the function of
ATDC may be dependent on cellular context. In none of these
reports was the role of ATDC in tumorigenesis examined in func-
tional studies.
We found that ATDC upregulated b-catenin levels in pancre-
atic cancer cell lines and primary pancreatic cancers. A large
body of data supports the contribution of activation of the
canonical (b-catenin-dependent) Wnt signaling pathway in the
development of colorectal cancer. Sustained b-catenin pathway
activation independent of APC, Axin1, or b-catenin mutations
has been demonstrated in a subset of breast and ovarian
cancers (Bafico et al., 2004). Mutations in APC or b-catenin
appear to be rare in pancreatic adenocarcinoma (Zeng et al.,
2006). While robust activation of the pathway due to signature
mutations in components of the b-catenin signaling cascade
that are commonly observed in other gastrointestinal cancers
is not present in pancreatic adenocarcinoma, immunohisto-
chemical analysis of b-catenin suggests a possible contribution
of b-catenin signaling during PanIN progression and the devel-
opment of invasive pancreatic cancer. Increased levels of both
cytoplasmic and nuclear b-catenin, indicative of b-catenin
signaling activity, have been reported in a substantial group of
pancreatic adenocarcinomas and PanINs (Pasca di Magliano
et al., 2007; Zeng et al., 2006). Pasca di Magliano and colleagues
reported that 65% of pancreatic cancers exhibit an increase
in either cytoplasmic and/or nuclear b-catenin. Similar
results were obtained in Pdx-Cre;KrasG12D and Pdx-Cre;
KrasG12D;p53F/+ transgenic mice that developed PanIN lesions
and subsequent invasive pancreatic cancers that were pheno-
typically indistinguishable from human pancreatic adenocarci-
nomas. Moreover, the authors showed that cancer cell survival216 Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc.and proliferation depend on b-catenin signaling activity in
multiple human pancreatic cancer cell lines.
The mechanisms by which ATDC levels are upregulated in
pancreatic adenocarcinomas remain unclear. Interestingly,
Pasca di Magliano and colleagues (2007) demonstrated that
increased Hedgehog signaling, one of the earliest changes in
PanIN lesions, activates b-catenin signaling in transgenic mice
and untransformed pancreatic ductal cells, suggesting that
Hedgehog may play a role in upregulating b-catenin activity in
some pancreatic adenocarcinomas. A possible connection
between Hedgehog upregulation and ATDC expression in
human pancreatic cancer cell lines or primary tumors remains
to be explored.
The levels of the free cytoplasmic pool of b-catenin are known
to be regulated by Wnt ligands. In the absence of an activating
Wnt signal, mediated viaWnt binding to the Frizzled/LRP5/6 cor-
eceptor complex, cytoplasmic b-catenin is destabilized by amul-
tiprotein complex containing axin, GSK-3b, and APC. Axin acts
as the scaffold of this complex and interacts with the other
components—b-catenin, APC, and GSK-3b. Interaction of
GSK-3b with axin in the complex facilitates efficient phosphory-
lation of b-catenin by GSK-3b. Phosphorylated b-catenin is then
ubiquitinated, leading to its rapid proteasomal degradation. We
found that ATDC bound to axin andGSK-3b in pancreatic cancer
cells, suggesting that ATDC interacts with the destruction
complex to prevent phosphorylation and subsequent ubiquitina-
tion of b-catenin.
When Wnt binds to the Frizzled/LRP coreceptors at the cell
surface, a cytoplasmic protein, Dvl, antagonizes GSK-
3b-dependent phosphorylation of b-catenin. Although it is not
known whether Dvl binds directly to the Frizzled/LRP coreceptor
or whether intermediary proteins are involved in the signal trans-
duction between Frizzled and Dvl, Dvl appears to bind to axin
and inhibit GSK-3b-dependent phosphorylation of b-catenin,
APC, and axin. Once the phosphorylation of b-catenin is
reduced, b-catenin dissociates from the axin complex, resulting
in its accumulation in the cytoplasm. Once stabilized, a fraction
of the b-catenin is translocated to the nucleus, where it binds
to transcription factors such as the TCF/lymphoid enhancer-
binding factor and thereby stimulates the transcription of b-cat-
enin target genes. We noted that ATDC expression in HEK293
cells induces expression of Dvl-2 and demonstrated that ATDC
forms a complex with Dvl-2 in pancreatic cancer cells. We also
demonstrated that levels of ATDC in primary pancreatic cancers
correlate well with Dvl-2 levels, suggesting that ATDC upregu-
lates Dvl-2 levels in primary pancreatic cancers and increases
b-catenin levels by this mechanism. We further showed that
knockdown of Dvl-2 in ATDC-expressing cells abrogates
enhanced TCF activity and cell proliferation induced by ATDC,
directly implicating Dvl-2 as an intermediary in this process.
The regulation of the Disheveled protein is still poorly under-
stood, but recent data suggest that Disheveled, like b-catenin,
may be controlled by ubiquitination and degradation by the pro-
teasome (Hershko and Ciechanover, 1998; Miyazaki et al., 2004;
Simons et al., 2005). Dvl-1 has been reported to interact with the
neuronal homologous to E6AP carboxyl terminus (HECT)-type
ubiquitin ligase NEDL1 (Miyazaki et al., 2004). The Wnt-induced
antagonist naked cuticle has been shown to modulate the
stability of Dvl-1 (Creyghton et al., 2005; Simons et al., 2005).
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3 ubiquitin ligase was shown to negatively regulate the Wnt/b-
catenin pathway by targeting Disheveled for degradation
(Angers et al., 2006). We found that ATDC increased Dvl-2 levels
not by changes inDvl-2 gene expression but rather by enhancing
the stability of the Dvl-2 protein, supporting that changes in Dvl
stability serve as an important mechanism in regulating the
Wnt/b-catenin signaling pathway.
The data in the present study support the following model for
the mechanism by which ATDC functions to promote the onco-
genesis of pancreatic cancer cells (Figure 8). In unstimulated,
normal pancreatic cells lacking ATDC, Dvl-2 is in the cytoplasm
and is not bound to the axin/GSK-3b/APC destruction complex.
This allows the destruction complex to phosphorylate b-catenin
and target it for ubiquitin-mediated degradation. In pancreatic
cancer cells expressing high levels of ATDC, ATDC binds to
and stabilizes Dvl-2, resulting in the release of b-catenin from
the destruction complex, increased b-catenin levels, and subse-
quent activation of downstream b-catenin/TCF-regulated target
genes These studies define a functional role of ATDC in human
tumorigenesis and, besides highlighting ATDC as a potential
therapeutic target in pancreatic cancer, define a mechanism
for activating Wnt/b-catenin signaling in cancer.
EXPERIMENTAL PROCEDURES
Cell Lines and Human Samples
The human pancreatic ductal adenocarcinoma cell lines Panc1, MiaPaCa2,
andBxPC3 and the human embryonic kidney cell line HEK293were purchased
from the American Type Culture Collection (ATCC). Fresh-frozen and paraffin-
embedded human pancreatic tissues were obtained from patients undergoing
surgical resection at the University of Michigan Medical Center. All human
Figure 8. Model of How ATDC Mediates Activation of b-Catenin
Signaling in Pancreatic Cancer Cells
Left: in unstimulated normal pancreatic cells lacking ATDC, Disheveled (Dvl) is
in the cytoplasm and is not bound to the axin/GSK-3b/APC destruction
complex. This allows the destruction complex to phosphorylate b-catenin
and target it for ubiquitin-mediated degradation.
Right: in pancreatic cancer cells expressing high levels of ATDC, ATDC binds
to stabilized Dvl, bringing it to the b-catenin destruction complex. Binding of
ATDC and Dvl to the destruction complex inhibits destruction complex func-
tion, resulting in the release of b-catenin from the destruction complex, leading
to increased b-catenin levels and subsequent activation of downstream target
genes.samples were obtained following approval by the Institutional Review Board
of the University of Michigan Medical Center. A pancreatic cancer tissue
microarray constructed by the University of Michigan Medical Center’s Tissue
Procurement Facility contained 5 samples of normal pancreas and 47 samples
of pancreatic adenocarcinoma and was used for immunohistochemical anal-
ysis of ATDC expression. Twenty-five paraffin-embedded human pancreatic
tissue samples containing pancreatic intraepithelial neoplasia (PanIn) lesions
of various stages were analyzed for ATDC expression using an anti-ATDC anti-
body. ATDC expression in PanIn lesions was evaluated by an experienced
pancreatic pathologist and graded as absent or present.
Constructs
The cDNA of human ATDC (kindly provided by J. Murnane, University of Cal-
ifornia, San Francisco) was subcloned into the pcDNA3.1 expression vector
(Invitrogen). Sequence analysis after cloning showed 100% homology to the
published sequence of ATDC. The methods used to create the control shRNA
and ATDC shRNA constructs are listed in the Supplemental Experimental
Procedures. Endogenous Dvl-2 was knocked down by transient transfection
of specific Dvl-2 shRNA1 and 2 (OriGene Technologies) in HEK293 and
MiaPaCa2 cells with or without ATDC overexpression. A reporter plasmid
carrying three TCF binding sites upstream of a minimal c-fos promoter driving
the firefly luciferase gene (TOPflash), a plasmid carrying the mutated TCF
binding sites upstream of a minimal c-fos promoter driving luciferase expres-
sion (FOPflash), and the expression constructs of wild-type or constitutively
active b-catenin containing a missense mutation of serine to tyrosine at codon
33 (S33Y) were used (Caca et al., 1999). The pGEX-2T vector containing
C-terminal E-cadherin/glutathione S-transferase (GST) was generated as
described previously (Winer et al., 2006).
Creation of Stable Cell Lines
Details regarding the creation of HEK293 and MiaPaCa2 cell lines with stable
expression of ATDC and Panc1 and BxPC3 cells with silencing of ATDC using
shRNA can be found in the Supplemental Experimental Procedures.
Quantitative Real-Time RT-PCR
Total RNA from the human pancreatic ductal adenocarcinoma, normal
pancreas, and chronic pancreatitis specimens or Panc1 cells (with or without
ATDC shRNA) were isolated using TRIzol reagent (Invitrogen). To avoid ampli-
fication of genomic DNA, RNA was pretreated with DNase (DNA-Free Kit from
Applied Biosystems). cDNA synthesis was performed using a High-Capacity
cDNA Archive Kit (Applied Biosystems). The cDNA served as a template in
quantitative real-time RT-PCR utilizing TaqMan Fast Universal PCR Master
Mix and TaqMan Gene Expression assay probes for ATDC
(Hs00232590_m1), Dvl-2 (Hs01005253_ml), or ribosomal protein S6 (RPS6)
(Hs02339423_g1) (Applied Biosystems) and an ABI 7500 Fast Sequence
Detection System. All reactions were performed in triplicate. ATDC mRNA
expression of different group specimens was normalized to endogenous ribo-
somal protein S6. Relative ATDC mRNA levels are presented as unit values of
2DCt = 2(Ct (ribosomal protein S6)  Ct (ATDC)), where Ct is the threshold cycle value
defined as the fractional cycle number at which the target fluorescent signal
passes a fixed threshold above baseline.
Immunohistochemical Analysis
Paraffin-embedded pancreatic tissue sections (4 mm thick) were cut, deparaffi-
nized, and subjected to a heat-induced epitope retrieval step. Endogenous
peroxidase activity was blocked with 1% (v/v) hydrogen peroxide in distilled
water. Details of the immunohistochemical analysis can be found in the
Supplemental Experimental Procedures.
Luciferase Reporter Gene Assays
Pancreatic cancer cells (with or without b-catenin silencing) or HEK293 and
MiaPaCa2 cells (with or without ATDC overexpression) were transfected using
a Lipofectamine 2000 transfection kit (Invitrogen) according to the manufac-
turer’s instructions with 0.2 mg of the TOPflash or FOPflash reporter constructs
with orwithout varying amounts (0.2–2 mg) of constructs expressing eitherwild-
type b-catenin or S33Y (constitutively activated) mutant b-catenin or 25 ng of
a construct expressing b-galactosidase as an internal control. The total DNA
for each transfection was kept constant by adding empty pcDNA vector.Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc. 217
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ometer and normalized to b-galactosidase expression. Endogenous b-catenin
or Dvl-2 was silenced by stable expression of b-catenin shRNA or transient
expression of Dvl-2 shRNAs (OriGene Technologies). TCF transcriptional
activity was inhibited by transient transfection of dnTCF vector (Upstate).
Nuclear and Membrane Fractionation
Nuclear and cytoplasmic proteins were extracted using a NE-PER Nuclear and
Cytoplasmic Extraction Reagents Kit (Pierce). Membrane proteins were
extracted using a Mem-PER Eukaryotic Membrane Protein Extraction Kit
(Pierce) according to the manufacturer’s instructions.
C-Terminal E-Cadherin/GST Fusion-Mediated Precipitation of the
Free b-Catenin Pool
The free b-catenin pool in ATDC-transfected and control HEK293 cells was
measured using a C-terminal E-cadherin/glutathione S-transferase fusion
protein as described previously (Winer et al., 2006).
Immunoblot Analysis
Immunoblot analysis was performed as described previously (Zhang et al.,
2004). Details of the immunoblot analysis can be found in the Supplemental
Experimental Procedures.
Proliferation Assay
Cell proliferation was measured using a CellTiter 96 AQ nonradioactive cell
proliferation assay (Promega) as described previously (Zhang et al., 2004).
Coimmunoprecipitation Experiments
Cells were lysed by sonicating for 5 s in 1ml of detergent-free lysis buffer (PBS,
5 mM EDTA, 0.02% sodium azide, 10 mM iodoacetamide, 1 mM PMSF, and 2
mg leupeptin) at 4C. The lysates were cleared by microcentrifuging for 15 min
at 16,000 3 g at 4C. Antibody-conjugated beads were prepared by
combining 1 mg of polyclonal antibodies with 30 ml of a 50% protein A Sephar-
ose bead slurry in 0.5 ml of ice-cold PBS for 1 hr at 4C in a tube rotator and
were then washed two times with 1 ml of lysis buffer. The antibodies used
for coimmunoprecipitation were Dvl-2, b-catenin (Cell Signaling Technology),
axin, and GSK-3b (Upstate). Cell lysates (500 mg) were incubated with the
prepared beads and 10 ml of 10% BSA overnight at 4C. The beads were
washed four times with washing buffer (50 mM Tris-HCl [pH 7.4], 300 mM
NaCl, 5 mM EDTA, 0.02% sodium azide, 0.1% Triton X-100) and once with
ice-cold PBS. Proteins were revealed after SDS-PAGE and western blotting
with antibodies against FLAG (Sigma), Dvl-2, b-catenin, axin, GSK-3b, and
ATDC (Santa Cruz Biotechnology). Images were visualized using an ECL
detection system.
Pulse-Chase Assays
Cells were cultured to 70% confluence in six-well plates and then starved in
2 ml methionine-deficient DMEM (Sigma) for 30 min at 37C with 5% CO2.
Cells were pulse labeled with 100 mCi/ml [35S]methionine (Amersham Pharma-
cia) for 30 min at 37C. Labeled cells were chased in DMEM with a saturating
amount of cold methionine (2 mM) for various times and lysed in RIPA buffer
(10 mM Tris [pH 7.2], 158 mM NaCl, 1 mM EGTA, 1% Triton X-100, 1% deox-
ycholate, 0.1% SDS, 1 mM PMSF, and 13 Complete Protease Inhibitor Cock-
tail [RocheMolecular Biochemicals]). Total cell lysates were then prepared and
immunoprecipitated with a b-catenin antibody or Dvl-2 antibody and protein G
Sepharose beads (Invitrogen) for 3 hr at 4C. Immunocomplexes were sepa-
rated on SDS-PAGE gels (4%–20% gradient) and transferred to nitrocellulose.
The precipitates were subjected to autoradiography, and the densities of the
labeled proteins were analyzed by Kodak Gel Documentation System (model
1D 3.6).
In Vivo Tumorigenicity Studies
Six-week-old male NOD/SCID mice (Taconic) were housed under pathogen-
free conditions. Animal experiments were approved by the University of Mich-
igan Animal Care and Use Committee and were performed in accordance with
established guidelines. Mice were anesthetized with an intraperitoneal injec-
tion of xylazine (9 mg/kg) and ketamine (100 mg/kg). A median laparotomy
was performed, and 30 ml of media containing 53 105 Panc1 cells (expressing218 Cancer Cell 15, 207–219, March 3, 2009 ª2009 Elsevier Inc.control shRNA, ATDC shRNA1, or b-catenin shRNA stably transfected)
infected with a lentivirus encoding luciferase was injected into the pancreatic
tail using a 30G needle (n = 8 per group). To prevent leaking at the injection site,
the needle was withdrawn slowly and a sterile cotton swab was applied to the
injection site for 30 s. Bioluminescent imaging of mice was performed biweekly
using an IVIS 200 imaging system (Xenogen Biosciences). Sixty days after
cancer cell injection, mice were euthanized with carbon dioxide inhalation,
and autopsies were performed to assess the extent of primary tumor growth
and metastasis.
Statistical Analysis
Data are represented as mean ± SEM from at least three independent exper-
iments. Significance of differences between groups was evaluated by
Student’s t test or ANOVA. p < 0.05 was considered significant.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
eight figures and can be found with this article online at http://www.
cancercell.org/supplemental/S1535-6108(09)00027-0.
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